VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2016 | MPN highlights from EHA 2016

Srdan Verstovsek, MD, PhD of the University of Texas MD Anderson Cancer Center, Houston, TX discusses highlights in myeloproliferative neoplasm (MPN) research at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. As the EHA meeting is becoming more popular, more sessions on MPN are run. The sessions on the biology are dissecting the cause of hyperactive JAK/STAT pathway, which is abnormal in MPN patients. Further, he talks about prognostication, i.e. understanding these mutations and their effect. In terms of clinical studies, he highlights the RESPONSE-2 (NCT02038036) that was complementary to an earlier study that led to the approval of ruxolitinib, a JAK inhibitor, for polycythemia vera (PV) in second-line.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter